Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms 18F-flortanidazole, Flortanidazole F 18, Flortinidazole (18F) + [1] |
Target- |
Mechanism PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC9H11FN6O3 |
InChIKeyZSSPATINHRVRTN-LMANFOLPSA-N |
CAS Registry1070878-86-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Brain metastases | Phase 2 | NL | 01 May 2016 | |
Castration-Resistant Prostatic Cancer | Phase 2 | NL | 01 May 2016 | |
Esophageal Carcinoma | Phase 2 | NL | 01 May 2016 | |
Glioblastoma | Phase 2 | NL | 01 May 2016 | |
Hypoxia | Phase 2 | - | 01 Feb 2010 | |
Liver Cancer | Phase 2 | - | 01 Feb 2010 | |
Lung Cancer | Phase 2 | - | 01 Feb 2010 | |
Rectal Cancer | Phase 2 | - | 01 Feb 2010 | |
Uterine Cervical Cancer | Phase 2 | - | 01 Feb 2010 | |
Head and Neck Neoplasms | Phase 2 | - | 01 Feb 2010 |
Phase 2 | 50 | mpkwbdkjym(ghhcvjeodq) = ralagtgqrt unffbyehzm (qialatofjx, jkccbcpyvk - whlsdxqbqf) View more | - | 30 Aug 2013 |